Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

Vegivinti, Charan Thej Reddy; Evanson, Kirk W.; Lyons, H. A.; Akosman, Izzet; Barrett, Averi; Hardy, Nicole; Kane, Bernadette; Keesari, Praneeth Reddy; Pulakurthi, Yashwitha Sai; Sheffels, Erin; Balasubramanian, Prasanth; Chibbar, Richa; Chittajallu, Spandana; Cowie, Kathryn; Karon, John M.; Siegel, Lauren; Tarchand, Ranita; Zinn, Caleb; Gupta, Nitin; Kallmes, Kevin M.; Saravu, Kavitha; Touchette, Jillienne C.

doi:10.1186/s12879-022-07068-0

Cited by 70 publications

(55 citation statements)

References 104 publications

(218 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review provides a clinical overview of the first-generation oral antiviral agents against SARS-CoV-2. Parenteral therapeutics, including anti-spike monoclonal antibodies and remdesivir, are outside the scope of this article and are reviewed elsewhere [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

First-generation oral antivirals against SARS-CoV-2

Sendi

Razonable

Nelson

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

First-generation oral antivirals against SARS-CoV-2

Sendi

Razonable

Nelson

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

“…Several kinds of antiviral drugs have exhibited good therapeutic effects against SARS-CoV-2 infection, but no very safe or efficacious drugs have been submitted for improvement in mortality [110] , [170] , [171] . However, many physicians have tried to improve some complications of SARS-CoV-2 infection via administering a number of different drugs, which has been successful in several cases.…”

Section: Current Treatments For Patients With Cerebrovascular Complic...mentioning

confidence: 99%

Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?

Omidian

Mohammadi²,

Sadeghalvad³

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…More recently, oral antiviral agents have gained FDA EUA for use in COVID-19 [ 26 , 27 ]. Paxlovid, a combination of nirmatrelvir and ritonavir, was the first antiviral pill to gain EUA in the United States on 22 December 2021 [ 28 ].…”

Section: Clinical Trials Of Therapeutics For Covid-19 Pneumoniamentioning

confidence: 99%

Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus

Narayanan

Parimon

2022

IJMS

View full text Add to dashboard Cite

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality worldwide. Though previous coronaviruses have caused substantial epidemics in recent years, effective therapies remained limited at the start of the Coronavirus disease 19 (COVID-19) pandemic. The emergence and rapid spread throughout the globe of the novel SARS-CoV-2 virus necessitated a rapid development of therapeutics. Given the multitude of therapies that have emerged over the last two years and the evolution of data surrounding the efficacy of these therapies, we aim to provide an update on the major clinical trials that influenced clinical utilization of various COVID-19 therapeutics. This review focuses on currently used therapies in the United States and discusses the molecular mechanisms by which these therapies target the SARS-CoV-2 virus or the COVID-19 disease process. PubMed and EMBASE were used to find trials assessing the efficacy of various COVID-19 therapies. The keywords SARS-CoV-2, COVID-19, and the names of the various therapies included in this review were searched in different combinations to find large-scale randomized controlled trials performed since the onset of the COVID-19 pandemic. Multiple therapeutic options are currently approved for the treatment of SARS-CoV-2 and prevention of severe disease in high-risk individuals in both in the inpatient and outpatient settings. In severe disease, a combination of antiviral and immunomodulatory treatments is currently recommended for treatment. Additionally, anti-viral agents have shown promise in preventing severe disease and hospitalization for those in the outpatient setting. More recently, current therapeutic approaches are directed toward early treatment with monoclonal antibodies directed against the SARS-CoV-2 virus. Despite this, no treatment to date serves as a definitive cure and vaccines against the SARS-CoV-2 virus remain our best defense to prevent further morbidity and mortality.

show abstract

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

Cited by 70 publications

References 104 publications

First-generation oral antivirals against SARS-CoV-2

First-generation oral antivirals against SARS-CoV-2

Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?

Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus

Contact Info

Product

Resources

About